查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010930

腎癌治療市場：2026-2032年全球市場預測（按癌症類型、治療方法、給藥途徑、劑型和最終用戶分類）

Kidney Cancer Drugs Market by Cancer Type, Treatment Type, Route Of Administration, Dosage Form, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腎癌治療市場價值將達到 65.1 億美元，到 2026 年將成長至 68.9 億美元，到 2032 年將達到 99 億美元，複合年成長率為 6.16%。

主要市場統計數據
基準年 2025 65.1億美元
預計年份：2026年 68.9億美元
預測年份 2032 99億美元
複合年成長率 (%) 6.16%

對腎癌治療市場進行關鍵概述，重點在於科學進步、臨床實踐變化以及對相關人員的策略影響。

腎癌治療的現狀正進入一個快速發展的時期，這段時期涵蓋了科學、臨床和商業性多個方面，其驅動力來自生物學的突破性進展、臨床實踐的改進以及支付方趨勢的轉變。免疫腫瘤學和標靶治療的進步正在重塑治療模式，催生出新的治療方法組合和治療順序策略。這些都需要臨床醫生、支付方和產業負責人認真考慮。同時，以患者為中心的因素，例如耐受性、給藥便利性和生活品質，也日益影響治療方法選擇和研發的優先順序。

精準醫療、免疫腫瘤學的進步以及真實世界數據（REW）的整合如何全面重塑治療方法選擇和商業化策略。

隨著精準醫療、免疫腫瘤學進展和聯合治療的融合，腎癌治療格局正在發生變革性轉變，重新定義了治療標準。新型分子標靶療法擴大基於分子譜分析，從單一的治療方案轉向以生物標記主導的干涉，旨在最大限度地提高療效並最大限度地降低毒性。同時，包括查核點抑制劑和新型免疫調節劑在內的免疫療法策略日益成熟，正在擴大特定患者群體中持續緩解的範圍，並推動探索協同聯合治療的新型臨床試驗。

我們評估了近期關稅變化對營運程序和准入的影響，以及製造和籌資策略的韌性如何減輕這種干擾。

國家層級的政策變化會對藥品供應鏈、定價策略和市場進入連鎖反應，而近期關稅趨勢也對藥品採購、生產和分銷領域的相關人員帶來了新的複雜性。跨境貿易成本會影響籌資策略和策略採購決策，迫使製造商重新評估製造地、在地採購方案和庫存策略，以防止供應中斷並維持經濟競爭力。

基於細分的詳細見解，展示了癌症亞型、治療方法、劑型和臨床環境如何決定臨床開發和商業化途徑。

細分市場分析凸顯了治療藥物開發和商業化策略需要根據每種癌症類型、治療方法、給藥途徑、劑型和最終用戶的獨特臨床特徵和遞送特性進行客製化。基於癌症類型，腎細胞癌、腎肉瘤、移行細胞癌和威爾姆氏腫瘤的治療方案和臨床試驗設計有顯著差異。每種適應症都有其獨特的生物學因素、患者群體和臨床終點，這些因素會影響監管策略和臨床推廣途徑。因此，申辦方應制定與每種癌症亞型的自然病程和未滿足的醫療需求相符的實證方案。

美洲、歐洲、中東和非洲以及亞太地區的區域監管差異、支付方期望和臨床基礎設施都會對藥物的可及性和商業化產生影響。

區域趨勢對臨床試驗參與者招募、監管方式、定價預期和醫療服務模式均有顯著影響，因此，深入了解區域差異對於制定全球策略至關重要。在美洲，多樣化的支付模式和對創新的高度重視影響著新治療方法的發展軌跡，該地區產生的真實世界數據往往反映在支付方的決策和指南更新中。此外，主要學術研究中心的集中也為早期臨床試驗活動提供了支持，並有助於快速評估有前景的聯合治療和生物標記。

加速創新腎癌療法的開發、全球推廣和普及的企業策略方法和合作模式。

企業層面的發展趨勢反映了各公司不同的策略立場，從專注於生物製劑的專業公司到致力於建構整合腫瘤產品組合的多元化製藥公司，不一而足。主要企業傾向於集中投資於聯合療法、生物標記主導的適應症以及旨在向支付方證明永續臨床獲益和成本效益的真實世界研究項目。同時，中型和新興企業則經常致力於開發小眾適應症和創新給藥平台，以建立差異化的價值提案，並吸引策略合作夥伴關係和授權授權機會。

產業領導者應採取切實可行的策略步驟，協調生物標記開發、證據產生、供應彈性和商業性執行，以產生持久的影響。

行業領導者應採取多管齊下的策略，將科學重點與切實可行的商業化和市場准入策略相結合，以快速將有前景的治療方法轉化為永續的臨床應用。首先，經營團隊必須優先考慮以生物標記主導的研發，並投資於伴隨診斷，以確保患者選擇策略穩健且具有臨床可行性。這種策略的結合能夠降低研發風險，並透過在特定患者群體中證實標靶化獲益，增強醫保報銷的證據。

採用以證據主導的調查方法，結合文獻整合、專家諮詢、真實世界資料審查和嚴格的基於情境的分析來檢驗結果。

本報告的研究結合了多來源證據架構和嚴謹的分析方法，以確保得出全面且可重複的結論。主要資料輸入包括對同儕審查的臨床文獻、監管決策和指導文件的系統性回顧，並輔以對真實世界證據來源的檢驗和對臨床實踐模式的分析。透過整合這些要素，我們揭示了治療方法的演變、臨床應用趨勢以及對研發和商業化營運的影響。

結論強調，需要將創新科學與嚴謹的商業化和在地化策略結合，以改善患者的治療效果。

總之，腎癌治療領域呈現出快速創新、治療模式轉變以及日益重視具有顯著臨床和經濟價值的證據等特徵。標靶治療和免疫腫瘤學的進步正在拓展多種腎癌的治療選擇，而給藥方式的演變和醫療服務模式的轉變也持續影響著治療方案的採納。同時，供應鏈的韌性以及區域監管差異等運作因素對於確保患者獲得治療和維持治療的連續性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以癌症類型分類的腎癌治療市場

  • 腎臟細胞癌
  • 腎臟肉瘤
  • 移行細胞癌
  • 威爾姆氏腫瘤

第9章：腎癌治療市場（依治療方法分類）

  • 化療
  • 荷爾蒙療法
  • 免疫療法
  • 新治療方法
  • 標靶治療

第10章：腎癌治療市場：依給藥途徑分類

  • 靜脈注射
  • 口服

第11章：腎癌治療藥物市場（依劑型分類）

  • 膠囊
  • 注射藥物
  • 藥片

第12章：腎癌治療市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第13章：腎癌治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：腎癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腎癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腎癌治療市場

第17章：中國腎癌治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agensys, Inc.
  • Aravive, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • AVEO Pharmaceuticals, Inc.（an LG Chem company）
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Calithera Biosciences, Inc.
  • Cytokinetics, Incorporated
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Ipsen SA
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nektar Therapeutics
  • Novartis AG
  • Peloton Therapeutics, Inc.（a Merck & Co., Inc. company）
  • Pfizer Inc.
  • Roche Holding AG（F. Hoffmann-La Roche Ltd）
  • Surface Oncology, Inc.
Product Code: MRR-434CCDA0527F

The Kidney Cancer Drugs Market was valued at USD 6.51 billion in 2025 and is projected to grow to USD 6.89 billion in 2026, with a CAGR of 6.16%, reaching USD 9.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.51 billion
Estimated Year [2026] USD 6.89 billion
Forecast Year [2032] USD 9.90 billion
CAGR (%) 6.16%

A focused overview of the kidney cancer therapeutics landscape that frames scientific advances, clinical practice shifts, and strategic implications for stakeholders

The kidney cancer therapeutics landscape has entered a period of rapid scientific, clinical, and commercial evolution driven by breakthroughs in biology, refinements in clinical practice, and shifting payer dynamics. Advances in immuno-oncology and targeted agents have reframed treatment paradigms, creating new therapeutic combinations and sequencing strategies that demand careful scrutiny from clinicians, payers, and industry strategists. At the same time, patient-centric considerations such as tolerability, administration convenience, and quality of life are increasingly influencing therapeutic choice and development priorities.

As stakeholders navigate this complex environment, the interplay between regulatory decisions, real-world evidence generation, and commercial access pathways becomes critical. Regulatory authorities are adapting approval frameworks to accommodate novel mechanisms of action and accelerated pathways, while clinicians and multidisciplinary care teams are integrating evolving evidence into practice. Consequently, industry players must balance scientific innovation with pragmatic commercialization tactics that address real-world treatment patterns and system-level constraints. Transitioning from discovery to sustainable adoption therefore requires cross-functional alignment and foresight.

Ultimately, the introduction establishes a foundation for deeper analysis by outlining the primary drivers of change, the emerging therapeutic classes reshaping care, and the strategic imperatives that will define competitive advantage over the coming years. The intent is to orient readers toward the high-impact themes that warrant focused attention when assessing pipeline prioritization, partnership opportunities, and patient-access strategies.

How precision medicine, immuno-oncology progress, and real-world evidence integration are collectively reshaping therapeutic choices and commercialization strategies

The therapeutic landscape for kidney cancer is undergoing transformative shifts as precision medicine, immuno-oncology advances, and combination regimens converge to redefine standards of care. Emerging targeted therapies are increasingly informed by molecular profiling, prompting a move away from one-size-fits-all approaches toward biomarker-driven interventions that seek to maximize efficacy while mitigating toxicity. Concurrently, the maturation of immunotherapeutic strategies, including checkpoint inhibition and novel immune modulators, is expanding the range of durable responses for subsets of patients and prompting new trials that explore synergistic combinations.

In addition, the route and convenience of administration are catalyzing change; oral targeted agents and alternative dosing strategies are influencing patient adherence and site-of-care considerations. Parallel to clinical innovations, regulatory frameworks and reimbursement pathways are adapting to accommodate therapies with complex benefit-risk profiles, which in turn influences sponsor development strategies and post-approval evidence generation. Moreover, real-world data and patient-reported outcomes are playing an expanded role in demonstrating value and informing guideline updates.

These shifts collectively create opportunities for differentiation through combination science, companion diagnostics, and targeted real-world outcomes programs. For industry leaders, the imperative is to align scientific development with pragmatic access planning, invest in evidence-generation that resonates with payers and clinicians, and prepare organizational capabilities to support increasingly personalized treatment paradigms.

Assessing the practical operational and access ramifications of recent tariff shifts and how resilient manufacturing and procurement strategies can mitigate disruption

Policy changes at the national level can have cascading effects across pharmaceutical supply chains, pricing strategies, and market access efforts, and recent tariff dynamics have added a new layer of complexity for stakeholders involved in drug sourcing, manufacturing, and distribution. Cross-border trade costs have the potential to influence procurement strategies and strategic sourcing decisions, prompting manufacturers to reassess manufacturing footprints, local sourcing options, and inventory strategies to maintain uninterrupted supply and competitive economics.

As a result, companies with integrated manufacturing and diversified supplier bases are better positioned to absorb tariff-driven cost pressures, while smaller players may face heightened operational strain. In addition, health systems and specialty pharmacies that manage complex biologic and small-molecule therapeutics may need to adapt contracting practices and inventory management to preserve affordability and continuity of care. From a strategic perspective, organizations should prioritize supply chain visibility, scenario planning, and dialogue with payers to manage reimbursement impacts that arise indirectly from increased product costs.

Moving forward, coordinated planning across commercial, legal, and operations teams will be critical to mitigate tariff-related disruptions. Emphasizing resilience through nearshoring, dual sourcing, and flexible manufacturing can reduce exposure, while transparent stakeholder communication helps to preserve trust among clinicians and patients. Ultimately, integrating tariff considerations into strategic planning reduces execution risk and supports sustainable access to essential therapies.

Detailed segmentation-led insight showing how cancer subtype, treatment modality, route, dosage form, and care setting determine clinical development and commercialization pathways

Segmentation insights reveal that therapeutic development and commercialization strategies must be tailored to the distinct clinical and delivery characteristics of each cancer type, treatment modality, route of administration, dosage form, and end user. Based on Cancer Type, therapeutic programs and clinical trial designs differ markedly across Renal Cell Carcinoma, Renal Sarcoma, Transitional Cell Carcinoma, and Wilms Tumor, with each indication presenting unique biological drivers, patient demographics, and clinical endpoints that influence regulatory strategy and clinical adoption pathways. Consequently, sponsors should design evidence-generation plans that align with the natural history and unmet needs of each cancer subtype.

Based on Treatment Type, differentiation hinges on modality-specific considerations. Chemotherapy and hormone therapy retain roles in specific contexts, while immunotherapy and targeted therapy are increasingly central to treatment algorithms. Within immunotherapy, Checkpoint Inhibitors represent a pivotal class, and these agents further diverge into subcategories such as Cytokines and PD-1 Inhibitors, each carrying distinct mechanisms, toxicity profiles, and monitoring needs. Novel therapies, including cell-based and precision targeted constructs, introduce additional complexity in manufacturing and delivery that must be addressed early in development planning.

Based on Route Of Administration, the distinction between Intravenous and Oral delivery drives patient preference, site-of-care economics, and adherence considerations. Oral agents can shift therapy from infusion centers to outpatient management, altering payer mix and convenience for patients, whereas intravenous therapies may require infrastructure and resourcing at infusion sites. Based on Dosage Form, formulation decisions between Capsule, Injection, and Tablet affect pharmacokinetics, patient experience, and cold chain requirements. Finally, based on End User, differences among Ambulatory Surgical Centers, Hospitals, and Specialty Clinics shape contracting, reimbursement, and logistics. Integrating these segmentation dimensions into product development and commercial planning enables more precise targeting of clinical programs, reimbursement strategies, and provider engagement efforts.

How regional regulatory variance, payer expectations, and clinical infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific influence access and commercialization

Regional dynamics materially influence clinical trial enrollment, regulatory approaches, pricing expectations, and patterns of care, and a nuanced understanding of geographic variation is essential for global strategy. In the Americas, diverse payer models and a strong emphasis on innovation influence adoption trajectories for novel therapies, while real-world evidence generated in this region often informs payer decisions and guideline updates. Moreover, the concentration of leading academic centers supports early-phase trial activity, facilitating rapid evaluation of promising combinations and biomarkers.

In Europe, Middle East & Africa, heterogeneous regulatory environments and variations in reimbursement approaches require tailored access plans that reflect national-level health technology assessment processes and budgetary constraints. Stakeholders operating across these regions must align dossier development and health economic modelling with local evidentiary needs to navigate reimbursement pathways successfully. Transitioning eastward, the Asia-Pacific region spans mature health systems alongside emerging markets, each with distinct expectations regarding clinical evidence, pricing, and local manufacturing. Governments and private payers in this region are increasingly investing in oncology infrastructure and biomarker testing capacity, which in turn shapes demand for targeted therapies.

Taken together, regional strategies should be informed by local clinical practice patterns, regulatory timelines, and payer evidence requirements. Cross-border initiatives that leverage local partnerships, foster capacity building, and adapt commercial models to national contexts can accelerate access and optimize patient outcomes while respecting the unique operational realities of each geography.

Company strategic postures and partnership models that accelerate development, global reach, and access for innovative kidney cancer therapies

Company-level dynamics reflect diverse strategic postures ranging from focused biologics specialists to diversified pharmaceutical organisations pursuing integrated oncology portfolios. Leading developers tend to concentrate investments in combination science, biomarker-driven indications, and real-world outcomes programs designed to demonstrate durable clinical benefit and cost-effectiveness to payers. At the same time, midsized and emerging companies frequently pursue niche indications or innovative delivery platforms to carve differentiated value propositions and attract strategic partnerships or licensing opportunities.

In addition, the competitive environment incentivizes collaboration across the ecosystem: alliances between biotech innovators and established commercial organisations can accelerate late-stage development and expand global reach. Manufacturing partnerships and contract development collaborations are likewise crucial for managing the complex supply chains associated with biologics and cell therapies. Moreover, companies that invest early in post-approval evidence generation, patient support programs, and streamlined access solutions tend to enable smoother adoption of new therapies in diverse care settings.

Strategically, management teams should prioritize integrated planning that aligns clinical development, regulatory engagement, and market access activities. This approach reduces time-to-adoption risk, positions products competitively in crowded treatment landscapes, and enhances the potential for sustainable patient access across heterogeneous healthcare systems.

Practical strategic actions industry leaders should take to align biomarker development, evidence generation, supply resilience, and commercial execution for durable impact

Industry leaders should adopt a multi-dimensional playbook that aligns scientific priorities with pragmatic commercialization and access tactics, enabling rapid translation of promising therapies into sustainable clinical use. First, executives must prioritize biomarker-driven development and invest in companion diagnostics to ensure patient selection strategies are robust and clinically actionable. This alignment reduces development risk and strengthens the evidentiary case for reimbursement by demonstrating targeted benefit in defined patient subsets.

Second, organizations should proactively design post-approval evidence programs and real-world outcome studies that address payer and clinician questions about durability, safety in broader populations, and comparative effectiveness. These programs should be integrated with health economic models to support pricing and reimbursement dialogues. Third, resilience in supply chain and sourcing should be established through diversification, strategic partnerships, and contingency planning to mitigate the operational impact of external cost pressures. Fourth, companies must adapt commercial models to accommodate shifts in route of administration and care setting, ensuring that patient support services, specialty pharmacy strategies, and provider education programs are coordinated to facilitate uptake.

Finally, leaders should pursue collaborative models with academic centers, payers, and patient advocacy groups to co-create evidence, enhance trial enrollment, and align on value frameworks. By executing this set of actions, organizations can accelerate adoption while maintaining focus on patient outcomes and payer-relevant value propositions.

An evidence-driven research methodology combining literature synthesis, expert consultations, real-world data review, and scenario-based analytical rigor to validate insights

The research underpinning this report combined a multi-source evidence framework with rigorous analysis to ensure comprehensive, reproducible findings. Primary data inputs included systematic reviews of peer-reviewed clinical literature, regulatory decisions, and guidance documents, supplemented by an examination of real-world evidence sources and practice-pattern analyses. These elements were synthesized to map therapeutic evolution, clinical adoption trends, and the operational implications for development and commercialization.

In parallel, expert consultations with oncologists, health economists, reimbursement specialists, and supply chain professionals informed interpretation and contextualization of findings. These engagements helped validate assumptions about clinical practice, unmet needs, and payer considerations, and they guided prioritization of strategic recommendations. Analytical approaches incorporated qualitative synthesis of clinical and policy trends alongside scenario-based assessments of operational risks, ensuring that conclusions remain robust across plausible market conditions.

Finally, the methodology emphasized transparency and reproducibility: data sources and analytical frameworks were documented to enable stakeholders to trace insights back to original evidence streams. This structured approach supports confident decision-making and facilitates targeted follow-up analyses tailored to specific organizational questions.

Concluding synthesis emphasizing the need to combine innovative science with disciplined commercialization and regional strategies to improve patient outcomes

In conclusion, the kidney cancer therapeutics environment is characterized by rapid innovation, shifting care paradigms, and increasing emphasis on evidence that demonstrates meaningful clinical and economic value. Progress in targeted therapies and immuno-oncology has expanded therapeutic options across multiple renal cancer types, while evolving delivery formats and site-of-care dynamics continue to influence adoption. At the same time, operational considerations such as supply chain resilience and regional regulatory variance are central to enabling access and sustaining therapy continuity.

For stakeholders, the imperative is to integrate scientific ambition with pragmatic commercialization and access planning. This requires early alignment on biomarker strategies, investment in post-approval evidence generation that resonates with payers and clinicians, and proactive supply chain planning to mitigate external cost pressures. Moreover, regional differentiation in regulatory, payer, and clinical practice contexts mandates tailored strategies that reflect local realities while leveraging global capabilities.

Taken together, a balanced strategy that couples innovative science with disciplined execution will position organizations to deliver meaningful improvements in patient outcomes while navigating the complexities of a rapidly transforming therapeutic landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Kidney Cancer Drugs Market, by Cancer Type

  • 8.1. Renal Cell Carcinoma
  • 8.2. Renal Sarcoma
  • 8.3. Transitional Cell Carcinoma
  • 8.4. Wilms Tumor

9. Kidney Cancer Drugs Market, by Treatment Type

  • 9.1. Chemotherapy
  • 9.2. Hormone Therapy
  • 9.3. Immunotherapy
  • 9.4. Novel Therapies
  • 9.5. Targeted Therapy

10. Kidney Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Kidney Cancer Drugs Market, by Dosage Form

  • 11.1. Capsule
  • 11.2. Injection
  • 11.3. Tablet

12. Kidney Cancer Drugs Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Kidney Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Kidney Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Kidney Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Kidney Cancer Drugs Market

17. China Kidney Cancer Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agensys, Inc.
  • 18.6. Aravive, Inc.
  • 18.7. Arrowhead Pharmaceuticals, Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. AVEO Pharmaceuticals, Inc. (an LG Chem company)
  • 18.10. Bayer AG
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Calithera Biosciences, Inc.
  • 18.13. Cytokinetics, Incorporated
  • 18.14. Eisai Co., Ltd.
  • 18.15. Exelixis, Inc.
  • 18.16. Ipsen SA
  • 18.17. Johnson & Johnson
  • 18.18. Merck & Co., Inc.
  • 18.19. Nektar Therapeutics
  • 18.20. Novartis AG
  • 18.21. Peloton Therapeutics, Inc. (a Merck & Co., Inc. company)
  • 18.22. Pfizer Inc.
  • 18.23. Roche Holding AG (F. Hoffmann-La Roche Ltd)
  • 18.24. Surface Oncology, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL KIDNEY CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL KIDNEY CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY RENAL SARCOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TRANSITIONAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY WILMS TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY NOVEL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. GCC KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. G7 KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. NATO KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA KIDNEY CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA KIDNEY CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)